October 3, 2019

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street N.E.

Washington, D.C. 20549

Re:	ADC Therapeutics SA
	Request to Withdraw Registration Statement on Form F-1
	Registration No. 333-233659

Ladies and Gentlemen:

ADC Therapeutics SA (the “Company”) respectfully requests, pursuant to Rule 477(a) under the Securities Act of 1933, as amended (the “Act”), the immediate withdrawal of its Registration Statement on Form F-1 (Registration No. 333-233659), initially filed with the Securities and Exchange Commission (the “Commission”) on September 6, 2019, together with all exhibits and amendments thereto (collectively, the “Registration Statement”).  The Company is requesting withdrawal of the Registration Statement because it does not plan to pursue a public offering in the United States at this time. In addition, none of the Company’s securities were sold pursuant to the Registration Statement.

The Company also requests that, in accordance with Rule 457(p) of the Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use.

Very truly yours,

/s/ Dominique Graz

Dominique Graz

General Counsel

ADC Therapeutics SA